|
Sipavibart
Sipavibart is an experimental medication under investigation for the prevention of COVID‑19 in people who are immunocompromised.[1] Sipavibart is a recombinant human IgG1 monoclonal antibody that provides passive immunization against SARS-CoV-2 by binding its spike protein receptor binding domain.[1][2] Society and cultureLegal statusIn December 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Kavigale, intended for the prevention of COVID‑19 in immunocompromised people aged twelve years of age and older.[1] Kavigale was reviewed under the EMA's accelerated assessment program.[1] The applicant for this medicinal product is AstraZeneca AB.[1] NamesSipavibart is the international nonproprietary name.[3] References
Further reading
|
||||||||||||||||||||||
.svg){kind=small}
